Wytwarzanie produktów leczniczych jest dla nas nie tylko kwestia wykonania pewnego procesu technologicznego, ale misją związaną z człowiekiem opartą na wysokim standardzie jakości, bezpieczeństwa i skuteczności leków.
Mamy aktywną i kluczową rolę w podnoszeniu standardów życia codziennego. Sprawiamy, że społeczeństwo jest lepiej poinformowane, zdrowsze, szczęśliwsze i bezpieczniejsze
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 17 January 2012 up to and including 23 January 2013 the Company bought 20763 own shares representing 0.016% of the share capital of the Company, to the total value of BGN 44605.9 on the Bulgarian Stock Exchange. The average price per share was BGN 2.15.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 3511694, representing 2.66% of the share capital of the Company.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 24 January 2012 up to and including 30 January 2013 the Company bought 30477 own shares representing 0.023% of the share capital of the Company, to the total value of BGN 71646.72 on the Bulgarian Stock Exchange. The average price per share was BGN 2.35.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 3542171, representing 2.68% of the share capital of the Company.
The Board of Directors of Sopharma AD (the “Company”) notifies that for December 2012 Sopharma AD realized decrease of sales revenues of 13% compared to the same period of 2011, including 9% decrease of domestic sales and 17% decrease of export sales.
During the past twelve months Sopharma AD recorded an increase of sales revenues of 0.4%, including 9% decrease of domestic sales and 5% increase of export sales compared to 2011.
The Board of Directors of Sopharma AD (the “Company”) hereby notifies that on 23 January 2013 Sopharma AD received a notification of disclosure of shareholdings from Financial Consulting Company regarding the selling of 4 053 002 shares. After this transaction the share of Financial Consulting Company in the capital of Sopharma AD decreased below 10% to 9.62 %.
The date of registration of the transaction with the Central Depository AD is 23 January 2013.
The Board of Directors of Sopharma AD (the “Company”) hereby notifies that on 23 January 2013 Sopharma AD received a notification of disclosure of shareholdings from Donev Investments Holding AD regarding the purchasing of 2 982 666 shares. After this transaction the share of Donev Investments Holding AD in the capital of Sopharma AD increased above 25% to 26.78%.
The date of registration of the transaction with the Central Depository AD is 23 January 2013.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 10 January 2012 up to and including 16 January 2013 the Company bought 1000 own shares representing 0.00076% of the share capital of the Company, to the total value of BGN 2100 on the Bulgarian Stock Exchange. The average price per share was BGN 2.10.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The total number of own shares after these transactions is 3490931, representing 2.64% of the share capital of the Company.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 20 December 2012 up to and including 2 January 2013 the Company bought 1700 own shares representing 0.0013% of the share capital of the Company, to the total value of BGN 3631.00 on the Bulgarian Stock Exchange. The average price per share was BGN 2.14.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
For the month of December, 2011 Sopharma AD realized growth of sales revenues of 38% compared with the same month of the previous year, including 48% growth of domestic sales and 29% growth of export sales. The economic and political environment in Europe, the echo of the world crises and a number of administrative obstacles limited the growth rates during 2011. Sales revenues reached almost 210 million BGN and grew with 0.41%, including 3.32% growth of the domestic market and 0.86% decrease of exports compared with the same period of 2010.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from January 03 2012 up to and including January 06 2012 the Company bought 459 own shares representing 0.00034% of the share capital of the Company, to the total value of BGN 1460 on the Bulgarian Stock Exchange. The average price per share was BGN 3.19.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that on January 06 2012 the Company bought 11 150 shares from the capital of the company Hydroizomat AD. With this deal Sopharma AD has increased its holdings in the capital of the above-mentioned company over 5%. Sopharma AD now holds 65 222 shares or 5.02% of the capital of Hydroizomat AD. The total capital of the company is 1 299 122 shares.
